Quantcast

West LA Times

Saturday, November 23, 2024

GT Biopharma Announces Two Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting

GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary natural killer (NK) cell engager, TriKE® platform, today announced two poster presentations at the Society for Immunotherapy of Cancer’s 37th Annual Meeting (SITC 2022), to be held in Boston, Massachusetts and virtually on November 8-12, 2022. The two posters will highlight preclinical data on tri-specific NK cell engagers for the treatment of mesothelioma and prostate cancer.

Poster Presentations

Title: Tri-specific killer engagers target natural killer cells towards mesothelioma

Abstract Number: 1202

Presenter: Pippa Kennedy and Martin Felices

Date: November 11, 2022

Location and time: Poster Hall from 9:00am – 8:30pm ET

Title: Enhancing NK cell function in the 'cold' tumor microenvironment of prostate cancer with a novel Tri-specific Killer Engager against prostate-specific membrane antigen (PSMA)

Abstract Number: 1204

Presenter: Shee Kwan Phung and Martin Felices

Date: November 11, 2022

Location and time: Poster Hall from 9:00am – 8:30pm ET

Original source can be found here.

ORGANIZATIONS IN THIS STORY

!RECEIVE ALERTS

The next time we write about any of these orgs, we’ll email you a link to the story. You may edit your settings or unsubscribe at any time.
Sign-up

DONATE

Help support the Metric Media Foundation's mission to restore community based news.
Donate

MORE NEWS